IRIS Accounts Production v24.1.9.2 09199666 director 1.1.23 31.12.23 31.12.23 5.6.2024 0 0 true false true false false true false Auditors Opinion iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh091996662022-12-31091996662023-12-31091996662023-01-012023-12-31091996662021-12-31091996662022-01-012022-12-31091996662022-12-3109199666ns14:PoundSterling2023-01-012023-12-3109199666ns10:Director12023-01-012023-12-3109199666ns10:PrivateLimitedCompanyLtd2023-01-012023-12-3109199666ns10:SmallEntities2023-01-012023-12-3109199666ns10:Audited2023-01-012023-12-3109199666ns10:SmallCompaniesRegimeForDirectorsReport2023-01-012023-12-3109199666ns10:SmallCompaniesRegimeForAccounts2023-01-012023-12-3109199666ns10:FullAccounts2023-01-012023-12-3109199666ns5:CurrentFinancialInstruments2023-12-3109199666ns5:CurrentFinancialInstruments2022-12-3109199666ns5:ShareCapital2023-12-3109199666ns5:ShareCapital2022-12-3109199666ns5:FurtherSpecificReserve2ComponentTotalEquity2023-12-3109199666ns5:FurtherSpecificReserve2ComponentTotalEquity2022-12-3109199666ns5:RetainedEarningsAccumulatedLosses2023-12-3109199666ns5:RetainedEarningsAccumulatedLosses2022-12-3109199666ns5:CostValuation2022-12-3109199666ns5:CurrentFinancialInstrumentsns5:WithinOneYear2023-12-3109199666ns5:CurrentFinancialInstrumentsns5:WithinOneYear2022-12-31
REGISTERED NUMBER: 09199666















BREAS TECHNOLOGIES (UK) LIMITED

FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023






BREAS TECHNOLOGIES (UK) LIMITED (REGISTERED NUMBER: 09199666)






CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023




Page

Balance Sheet 1

Notes to the Financial Statements 2


BREAS TECHNOLOGIES (UK) LIMITED (REGISTERED NUMBER: 09199666)

BALANCE SHEET
31 DECEMBER 2023

2023 2022
Notes £    £    £    £   
FIXED ASSETS
Investments 4 9,375,551 9,375,551

CURRENT ASSETS
Debtors 5 736,925 737,843

CREDITORS
Amounts falling due within one year 6 1,200 1,200
NET CURRENT ASSETS 735,725 736,643
TOTAL ASSETS LESS CURRENT
LIABILITIES

10,111,276

10,112,194

CAPITAL AND RESERVES
Called up share capital 1 1
Capital Contribution Reserve 12,028,780 12,028,780
Retained earnings (1,917,505 ) (1,916,587 )
SHAREHOLDERS' FUNDS 10,111,276 10,112,194

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Profit and Loss Account has not been delivered.

The financial statements were approved by the director and authorised for issue on 5 June 2024 and were signed by:





Y Liu - Director


BREAS TECHNOLOGIES (UK) LIMITED (REGISTERED NUMBER: 09199666)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023

1. STATUTORY INFORMATION

Breas Technologies (UK) Limited is a private company limited by shares. The company is registered in England under number 09199666 and the address of the registered office is Barclays Bank Chambers, Bridge Street, Stratford-upon-Avon, Warwickshire, CV37 6AH. The company's place of business is Unit A2, The Bridge Business Centre, Timothy's Bridge Road, Stratford-upon-Avon, Warwickshire, CV37 9HW.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Preparation of consolidated financial statements
The company has not prepared consolidated financial statements in accordance with the available exemption under section 401 of the Companies Act 2006.

The accounts present information about the company as an individual undertaking and not about its group.

Investments in subsidiaries
Investments in subsidiary undertakings are recognised at cost.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Profit and Loss Account based on the fact that group relieved losses have been paid for.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was NIL (2022 - NIL).

BREAS TECHNOLOGIES (UK) LIMITED (REGISTERED NUMBER: 09199666)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 DECEMBER 2023

4. FIXED ASSET INVESTMENTS
Shares in
group
undertakings
£   
COST
At 1 January 2023
and 31 December 2023 9,375,551
NET BOOK VALUE
At 31 December 2023 9,375,551
At 31 December 2022 9,375,551

5. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2023 2022
£    £   
Amounts owed by group undertakings 736,924 737,842
Other debtors 1 1
736,925 737,843

6. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2023 2022
£    £   
Other creditors 1,200 1,200

7. DISCLOSURE UNDER SECTION 444(5B) OF THE COMPANIES ACT 2006

The Report of the Auditors was unqualified.

Robert Bowen BA(Hons) FCA (Senior Statutory Auditor)
for and on behalf of H L Barnes, Statutory Auditors

8. CONTROL

The immediate parent company is Breas Medical Holdings AB, incorporated in Sweden.

The immediate intermediate holding company is Fosun Medical Holdings AB, a company incorporated in Sweden. Further intermediate holding companies are Fosun Industrial Co., Ltd, a company incorporated in China. The ultimate holding company is Shanghai Fosun Pharmaceutical (Group) Co., Limited a company whose shares are listed on the Main Board of the Hong Kong Stock Exchange (stock code: 2196).

The smallest and largest group in which the company's accounts and the accounts of its subsidiary Breas Medical Limited are consolidated is that headed by Shanghai Fosun Pharmaceutical (Group) Co., Limited.